

In re Application of: Houghton, et al.
Serial No.: 09/768,445
Filed: January 24, 2001
Page 2

Amendments to the Specification

Please amend Page 3, Lines 1-5 of the Specification as follows:

or a pharmaceutically acceptable salt thereof. Irinotecan is preferably in the form of a hydrochloride salt. The synthesis of irinotecan and its salts is well known, and is described, for example, in U.S. Patent 4,604,463. Irinotecan hydrochloride is available commercially in the form of ~~CAMPTOSAR~~ CAMPTOSAR™ Injection, sold by Pharmacia & Upjohn.

Please amend Page 6, Lines 11-16 of the Specification as follows:

A common, but tolerable, side effect of temozolomide is nausea and vomiting. This can be alleviated by administering an anti-emetic in conjunction with the temozolomide. It is preferred that an anti-emetic be given p.o. about 30 minutes before temozolomide administration. Examples of anti-emetics that may be administered, include, but are not limited to ~~Haldol, Benadryl, Ativan, Compazine, and Ondansetron~~ HALDOL™ (haloperidol), BENADRYL™ (diphenhydramine), ATIVAN™ (lorazepam), COMPAZINE™ (prochlorperazine maleate), AND ZOFRAN™ (ondansetron).